Avidity Biosciences (RNA) News Today $26.68 -0.23 (-0.85%) Closing price 04:00 PM EasternExtended Trading$26.68 0.00 (0.00%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. reduced its position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 3.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 450,144 shares of the biotechApril 15 at 3:22 AM | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Receives $66.69 Consensus PT from AnalystsApril 15 at 1:29 AM | americanbankingnews.comAvidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Avidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) have earned an average recommendation of "Buy" from the thirteen research firms that are covering the firm, MarketBeat reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 12 montApril 14 at 3:24 AM | marketbeat.comExodusPoint Capital Management LP Makes New $984,000 Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)ExodusPoint Capital Management LP bought a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 33,844 shares of the biotechnoloApril 13 at 4:47 AM | marketbeat.comGeode Capital Management LLC Boosts Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Geode Capital Management LLC boosted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 8.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,807,455 shares ofApril 13 at 4:39 AM | marketbeat.comFmr LLC Trims Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Fmr LLC trimmed its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,509,606 shares of the biotechnology company's stock after sellingApril 12 at 5:43 AM | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low - Here's WhyAvidity Biosciences (NASDAQ:RNA) Sets New 1-Year Low - Should You Sell?April 12 at 5:15 AM | marketbeat.comDynamic Technology Lab Private Ltd Takes $402,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Dynamic Technology Lab Private Ltd acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,830 shares of the biotechnologyApril 12 at 5:08 AM | marketbeat.comBeyond The Numbers: 13 Analysts Discuss Avidity Biosciences StockApril 11, 2025 | nasdaq.comAvidity Biosciences (NASDAQ:RNA) Shares Gap Down - Should You Sell?Avidity Biosciences (NASDAQ:RNA) Shares Gap Down - What's Next?April 11, 2025 | marketbeat.comAvidity Biosciences' (RNA) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Avidity Biosciences in a research note on Wednesday.April 11, 2025 | marketbeat.comAvidity Biosciences' (RNA) Buy Rating Reiterated at Needham & Company LLCApril 11, 2025 | americanbankingnews.comTrexquant Investment LP Acquires 60,685 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Trexquant Investment LP raised its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 383.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,495 shares of the biotechnology cApril 11, 2025 | marketbeat.comSei Investments Co. Sells 19,149 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Sei Investments Co. trimmed its holdings in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 47.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,554 shares of the biotechnology company's stock after selling 19,April 10, 2025 | marketbeat.com5RNA : Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences StockApril 9, 2025 | benzinga.comAvidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1April 8, 2025 | prnewswire.comFinepoint Capital LP Takes $11.38 Million Position in Avidity Biosciences, Inc. (NASDAQ:RNA)Finepoint Capital LP purchased a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 391,300 shares of the biotechnology company's stock,April 8, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by Schroder Investment Management GroupSchroder Investment Management Group boosted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 99.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 61,480 shares of the bioApril 8, 2025 | marketbeat.comNorges Bank Invests $21.08 Million in Avidity Biosciences, Inc. (NASDAQ:RNA)Norges Bank bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 724,787 shares of the biotechnology company's stocApril 8, 2025 | marketbeat.com14,044 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Bryce Point Capital LLCBryce Point Capital LLC purchased a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 14,044 shares of the biotechnology company's stock, valued at approximately $408,0April 7, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Acquired by Vanguard Group Inc.Vanguard Group Inc. grew its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,431,911 shares of the biotechnology company'sApril 6, 2025 | marketbeat.comAvidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your MoneyApril 5, 2025 | msn.comAvidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $163,501.25 in StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider Kathleen P. Gallagher sold 5,875 shares of the stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $27.83, for a total transaction of $163,501.25. Following the completion of the transaction, the insider now owns 50,554 shares of the company's stock, valued at approximately $1,406,917.82. The trade was a 10.41 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.April 5, 2025 | marketbeat.comKLP Kapitalforvaltning AS Takes $521,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA)KLP Kapitalforvaltning AS acquired a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 17,900 shares ofApril 5, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Still a Buy?Avidity Biosciences (NASDAQ:RNA) Stock Price Up 4.1% - Here's WhyApril 4, 2025 | marketbeat.comKathleen P. Gallagher Sells 5,875 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) StockApril 4, 2025 | insidertrades.comAvidity Biosciences, Inc. (NASDAQ:RNA) Shares Bought by Wellington Management Group LLPWellington Management Group LLP boosted its stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 15.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,106,097 shares of the biotechnology company's stock after purchasing an additionalApril 3, 2025 | marketbeat.comAvidity Biosciences completes enrollment in Phase 1/2 Fortitude trialApril 2, 2025 | markets.businessinsider.comPictet Asset Management Holding SA Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Pictet Asset Management Holding SA grew its stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 1.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 799,028 shares of the biotechnology companyApril 2, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Down 7% - Time to Sell?Avidity Biosciences (NASDAQ:RNA) Stock Price Down 7% - Here's WhyApril 1, 2025 | marketbeat.comAvidity Biosciences to Participate in Upcoming Investor ConferenceApril 1, 2025 | prnewswire.comAvidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular DystrophyMarch 31, 2025 | prnewswire.comArtisan Partners Limited Partnership Sells 314,028 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Artisan Partners Limited Partnership trimmed its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 23.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,015,251 shares of the biotechnology company's stMarch 30, 2025 | marketbeat.com9,534 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Acquired by Quantbot Technologies LPQuantbot Technologies LP acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 9,534 shares of the biotechnology company's stock, valMarch 30, 2025 | marketbeat.comNatixis Advisors LLC Makes New Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)Natixis Advisors LLC purchased a new stake in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 13,577 shares of the biotechnology company's stock, valued at aMarch 28, 2025 | marketbeat.comThe Risk/Reward Of Avidity Biosciences And Its 2 Promising ProgramsMarch 26, 2025 | seekingalpha.comEFG Asset Management North America Corp. Increases Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)EFG Asset Management North America Corp. lifted its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 94.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,March 26, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Trading 8.5% Higher - Time to Buy?Avidity Biosciences (NASDAQ:RNA) Trading Up 8.5% - Still a Buy?March 25, 2025 | marketbeat.comCibc World Markets Corp Acquires New Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)Cibc World Markets Corp bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,386 shares of the biotechnology company's stock,March 25, 2025 | marketbeat.comSwiss National Bank Acquires 18,800 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA)Swiss National Bank increased its holdings in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 12.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 174,400 shares of the biotechnology company's stockMarch 25, 2025 | marketbeat.com198,907 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Raymond James Financial Inc.Raymond James Financial Inc. bought a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 198,907 shares of the biotechnology company's stock, valuedMarch 25, 2025 | marketbeat.comMagnetar Financial LLC Acquires Shares of 22,003 Avidity Biosciences, Inc. (NASDAQ:RNA)Magnetar Financial LLC acquired a new stake in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 22,003 shares of the biotechnology company's stock, valued at aMarch 23, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Sells $246,461.10 in StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CFO Michael F. Maclean sold 7,935 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $31.06, for a total transaction of $246,461.10. Following the sale, the chief financial officer now directly owns 96,720 shares in the company, valued at $3,004,123.20. The trade was a 7.58 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 22, 2025 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 9,578 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) insider Steven George Hughes sold 9,578 shares of the company's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $31.06, for a total value of $297,492.68. Following the completion of the transaction, the insider now owns 72,850 shares of the company's stock, valued at $2,262,721. The trade was a 11.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 22, 2025 | marketbeat.comInsider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) CEO Sells 31,540 Shares of StockAvidity Biosciences, Inc. (NASDAQ:RNA - Get Free Report) CEO Sarah Boyce sold 31,540 shares of the business's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $31.06, for a total value of $979,632.40. Following the transaction, the chief executive officer now directly owns 305,871 shares in the company, valued at $9,500,353.26. This trade represents a 9.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.March 22, 2025 | marketbeat.comAvidity Biosciences, Inc. (NASDAQ:RNA) CFO Michael F. Maclean Sells 7,935 SharesMarch 22, 2025 | insidertrades.comIntech Investment Management LLC Increases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA)Intech Investment Management LLC raised its position in Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) by 64.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 60,801 shares of the biotechnology company's stock after acquiring an additional 23,765 shares dMarch 22, 2025 | marketbeat.comAvidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | prnewswire.comProficio Capital Partners LLC Makes New $1.76 Million Investment in Avidity Biosciences, Inc. (NASDAQ:RNA)Proficio Capital Partners LLC acquired a new position in shares of Avidity Biosciences, Inc. (NASDAQ:RNA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 60,457 shares of thMarch 20, 2025 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Down 7.9% - Time to Sell?Avidity Biosciences (NASDAQ:RNA) Stock Price Down 7.9% - Should You Sell?March 19, 2025 | marketbeat.com Remove Ads Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Media Mentions By Week RNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼1.020.80▲Average Medical News Sentiment RNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼177▲RNA Articles Average Week Remove Ads Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Genmab A/S News Today Dr. Reddy's Laboratories News Today Moderna News Today Ascendis Pharma A/S News Today Qiagen News Today Viatris News Today Roivant Sciences News Today Lantheus News Today Revolution Medicines News Today BridgeBio Pharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNA) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNA Stock Free RNA Stock Alerts